Enantiomeric fraction as an indicator of pharmaceutical biotransformation during wastewater treatment and in the environment - A review

Environmental Technology

Volumn 31, Issue 12, 2010, Pages 1349-1370

  Hashim, N H ^a,b   Shafie, S ^a   Khan, S J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITI TUN HUSSEIN ONN MALAYSIA   (Malaysia)

Author keywords

chiral PhACs; enantiomeric fraction; enantioseparation; wastewater treatment

Indexed keywords

BIOCONVERSION; DRUG PRODUCTS; DRUG PRODUCTS PLANTS; ENANTIOMERS; RECLAMATION; WASTEWATER; WATER TREATMENT PLANTS;

ANALYTICAL TECHNIQUES; AQUATIC ENVIRONMENTS; BIOTRANSFORMATION PROCESS; CHIRAL PHACS; CHIRAL PHARMACEUTICALS; CHIRAL STATIONARY PHASIS; DERIVATIZATIONS; DIASTEREOMERS; ENANTIOMERIC FRACTION; ENANTIOMERIC FRACTIONS; ENANTIOSELECTIVE; ENANTIOSELECTIVE ANALYSIS; ENANTIOSEPARATIONS; ENVIRONMENTAL SAMPLE; HISTORICAL RECORDS; PHARMACEUTICAL INDUSTRY; SCIENTIFIC LITERATURE; STATIONARY PHASIS;

WASTEWATER TREATMENT;

AQUATIC ENVIRONMENT; BIOTRANSFORMATION; HISTORICAL RECORD; LITERATURE REVIEW; PHARMACEUTICAL INDUSTRY; WASTEWATER; WATER POLLUTION; WATER TREATMENT;

ANALYTIC METHOD; BIOTRANSFORMATION; DRUG INDUSTRY; ENANTIOMER; HUMAN; INDUSTRIAL WASTE; REVIEW; SEPARATION TECHNIQUE; WASTE WATER; WASTE WATER MANAGEMENT; WATER POLLUTION INDICATOR;

EID: 77957578687     PISSN: 09593330     EISSN: 1479487X     Source Type: Journal    
DOI: 10.1080/09593331003728022     Document Type: Review

References (146)

1. J. Gal, The discovery of biological enantioselectivity: Louis Pasteur and the fermentation of tartaric acid, 1857 - A review and analysis 150 yr later, Chirality 20 (2008), pp. 5-19.
2. B. Chankvetadze, Enantioseparations by using capillary electrophoretic techniques: The story of 20 and a few more years, J. Chromatogr. B 1168 (2007), pp. 45-70.
3. C. S. Wong, Environmental fate processes and biochemical transformations of chiral emerging organic pollutants, Anal. Bioanal. Chem. 386 (2006), pp. 544-558.
4. H. Hühnerfuss and M. R. Shah, Enantioselective chromatography - A powerful tool for the discrimination of biotic and abiotic transformation processes of chiral environmental pollutants, J. Chromatogr. A 1216 (2009), pp. 481-502.
5. A. D. Leone, E. M. Ulrich, C. E. Bodnar, R. L. Falconer, and R. A. Hites, Organochlorine pesticide concentrations and enantiomer fractions for chlordane in indoor air from the US cornbelt, Atmos. Environ. 34 (2000), pp. 4131-4138.
6. T. F. Bidleman, F. Wong, C. Backe, A. Sodergren, E. Brorstrom-Lunden, P. A. Helm, and G. A. Stern, Chiral signatures of chlordanes indicate changing sources to the atmosphere over the past 30 years, Atmos. Environ. 38 (2004), pp. 5963-5970.
7. M. Venier and R. A. Hites, Chiral organochlorine pesticides in the atmosphere, Atmos. Environ. 41 (2007), pp. 768-775.
8. P. B. Kurt-Karakus, T. F. Bidleman, and K. C. Jones, Chiral organochlorine pesticide signatures in global background soils, Environ. Sci. Technol. 39 (2005), pp. 8671-8677.
9. P. B. Kurt-Karakus, J. L. Stroud, T. Bidleman, K. T. Semple, L. Jantunen, and K. C. Jones, Enantioselective degradation of organochlorine pesticides in background soils: Variability in field and laboratory studies, Environ. Sci. Technol. 41 (2007), pp. 4965-4971.
10. W. Liu, S. Qin, and J. Gan, Chiral stability of synthetic pyrethroid insecticides, J. Agric. Food Chemistry 53 (2005), pp. 3814-3820.
11. A. Monkiedje, M. Spiteller, and K. Bester, Degradation of racemic and enantiopure metalaxyl in tropical and temperate soil, Environ. Sci. Technol. 37 (2003), pp. 707-712.
12. S. N. Meijer, C. J. Halsall, T. Harner, A. J. Peters, W. A. Ockenden, A. E. Johnston, and K. C. Jones, Organochlorine pesticide residues in archived UK soil, Environ. Sci. Technol. 35 (2001), pp. 1989-1995.
13. L. M. M. Jantunen and T. F. Bidleman, Organochlorine pesticides and enantiomers of chiral pesticides in Arctic ocean water, Arch. Environ. Contam. Toxicol. 35 (1998), pp. 218-228.
14. H.-R. Buser, T. Poiger, and M. D. Müller, Occurrence and environmental behaviour of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater, Environ. Sci. Technol. 33 (1999), pp. 2529-2535.
15. L. J. Fono and D. L. Sedlak, Use of the chiral pharmaceutical propranolol to identify sewage discharges into surface waters, Environ. Sci. Technol. 39 (2005), pp. 9244-9252.
16. S. L. MacLeod, P. Sudhir, and C. S. Wong, Stereoisomer analysis of wastewater-derived [beta]-blockers, selective serotonin re-uptake inhibitors, and salbutamol by high-performance liquid chromatographytandem mass spectrometry, J. Chromatogr. A 1170 (2007), pp. 23-33.
17. V. Matamoros, M. Hijosa, and J. M. Bayona, Assessment of the pharmaceutical active compounds removal in wastewater treatment systems at enantiomeric level. Ibuprofen and naproxen, Chemosphere 75 (2009), pp. 200-205.
18. L. N. Nikolai, E. L. McClure, S. L. MacLeod, and C. S. Wong, Stereoisomer quantification of the beta-blocker drugs atenolol, metoprolol, and propranolol in wastewaters by chiral high-performance liquid chromatography-tandem mass spectrometry, J. Chromatogr. A 1131 (2006), pp. 103-109.
19. J. K. Stanley, A. J. Ramirez, C. K. Chambliss, and B. W. Brooks, Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate, Chemosphere 69 (2007), pp. 9-16.
20. J. K. Stanley, A. J. Ramirez, M. Mottaleb, C. K. Chambliss, and B. W. Brooks, Enantiospecific toxicity of the beta-blocker propranolol to Daphnia magna and Pimephales promelas, Environ. Toxicol. Chem 25 (2006), pp. 1780-1786.
21. K. Kummerer, A. Al-Ahmad, B. Bertram, and M. Wieler, Biodegradability of antineoplastic compounds in screening tests: Influence of glucosidation and of stereochemistry, Chemosphere 40 (2000), pp. 767-773.
22. S. L. MacLeod and C. S. Wong, Loadings, trends, comparisons, and fate of achiral and chiral pharmaceuticals in wastewaters from urban tertiary and rural aerated lagoon treatments, Water Res. Accepted Manuscript (2009).
23. M. Winkler, J. R. Lawrence, and T. R. Neu, Selective biodegradation of ibuprofen and clofibric acid in two model river biofilm systems, Water Res. 35 (2001), pp. 3197-3205.
24. H. Hühnerfuss, S. Selke, R. Kallenborn, J. Kuhlmann, and S. Weigel, Enzymatic transformation of chiral pharmaceuticals in the environment as revealed by enantioselective chromatography, Organohalogen Compounds 68 (2006), pp. 17-20.
25. J. Caldwell and I. W. Wainer, Stereochemistry: Definitions and a note on nomenclature, Human Psychopharm. Clin. 16 (2001), pp. S105-S107.
26. L. G. Wade, Precision in stereochemical terminology, J. Chem. Educ. 83 (2006), pp. 1793-1794.
27. C. A. Challener, Chiral Drugs, Ashgate Publishing Limited, Hampshire, UK, 2001.
28. R. S. Cahn, C. K. Ingold, and V. Prelog, The specification of asymmetric configuration in organic chemistry, Experientia (1956), pp. 81-124.
29. V. Wsol, Chiral inversion of drugs: Coincidence or principle?, Curr. Drug. Metab. 5 (2004), pp. 517-533.
30. M. Reist, B. Testa, P.-A. Carrupt, and M. J. V. Schurig, Racemization, enantiomerization, diastereomerization, and epimerization: Their meaning and pharmacological significance, Chirality 7 (1995), pp. 396-400.
31. T. A. Baillie, W. J. Adams, D. G. Kaiser, L. S. Olanoff, G. W. Halstead, H. Harpootlian, and G. J. Van Giessen, Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans, J. Pharmacol. Exp. Ther. 249 (1989), pp. 517-523.
32. E. J. D. Lee, G. Williams, R. Day, G. Graham, and D. Champion, Stereoselective disposition of ibuprofen in man, Brit. J. Clin. Pharmaco. 19 (1985), pp. 669-674.
33. S. W. Smith, Review: Chiral toxicology: It's the same thing... only different, Toxicol. Sci. 110 (2009), pp. 4-30.
34. H. de Geus, P. G. Wester, P. de Boer, and U. A. T. Brinkman, Enantiomer fractions instead of enantiomer ratios, Chemosphere 41 (2000), pp. 725-727.
35. R. E. Gawley, Do the Terms '%ee' and '%de' make sense as expressions of stereoisomer composition or stereoselectivity? J. Org. Chem. 71 (2006), pp. 2411-2416.
36. W. Vetter, Enantioselective fate of chiral chlorinated hydrocarbons and their metabolites in environmental samples, Food. Rev. Int. 17 (2001), pp. 113-182.
37. T. Harner, K. Wiberg, and R. Norstrom, Enantiomer fractions are preferred to enantiomer ratios for describing chiral signatures in environmental analysis, Environ. Sci. Technol. 34 (2000), pp. 118-120.
38. E. M. Ulrich, D. R. Helsel, and W. T. Foreman, Complications with using ratios for environmental data: Comparing enantiomeric ratios (ERs) and enantiomer fractions (EFs), Chemosphere 53 (2003), pp. 531-538.
39. J. McConathy and M. J. Owens, Stereochemistry in drug action, Primary Care Companion J. Clin. Phsychiatry 5 (2003), pp. 70-73.
40. J. Caldwell, Stereochemical determinants of the nature and consequences of drug metabolism, J. Chromatogr. A 694 (1995), pp. 39-48.
41. T. Laird, A cascade of inadequacy, Chem-Ind London 13 (1990), pp. 418-419.
42. A. Richards and R. McCague, The impact of chiral technology on the pharmaceutical industry, Chem-Ind London 11 (1997), p. 422-425.
43. J. Patocka and A. Dvoral, Biomedical aspects of chiral molecules, J. Appl. Biomed. 2 (2004), pp. 95-100.
44. T. Eriksson, S. Bjorkman, and P. Hoglund, Clinical pharmacology of thalidomite, Eur J. Clin. Pharmacol 57 (2001), pp. 365-376.
45. T. Eriksson, S. Bjorkman, B. Roth, A. Fyge, and P. Hoglund, Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis, Chirality 10 (1998), pp. 223-228.
46. T. Sjoerdsma, M. Kamermans, and H. Spekreijse, Effect of the tuberculostaticum ethambutol and stimulus intensity on chromatic discrimination in man, Vision Res. 39 (1999), pp. 2955-2962.
47. S. Sangita and S. Ray, Impact of chirality on drug action, J. Indian Chem. Soc. 83 (2006), pp. 315-326.
48. P. J. Barnes, Treatment with (R)-albuterol has no advantage over racemic albuterol, Am. J. Resp. Crit. Care 174 (2006), pp. 969-174.
49. P. Mansfield, D. Henry, and A. Tonkin, Singleenantiomer drugs: Elegant science, disappointing effects, Clin. Pharmacokinet. 43 (2004), pp. 287-290.
50. I. Agranat, H. Caner, and J. Caldwell, Putting chirality to work: The strategy of chiral switches, Nat. Rev. Drug Discov. 1 (2002), pp. 753-768.
51. H. Caner, E. Groner, L. Levy, and I. Agranat, Trends in the development of chiral drugs, Drug Discov. Today 9 (2004), pp. 105-110.
52. H. Murakami, From racemates to single enantiomerschiral synthetic drugs over the last 20 years, Top Curr. Chem. 269 (2007), pp. 273-299.
53. H. R. Buser, T. Poiger, and M. D. Muller, Changed enantiomer composition of metolachlor in surface water following the introduction of the enantiomerically enriched product to the market, Environ. Sci. Technol. 34 (2000), pp. 2690-2696.
54. D. Liu, P. Wang, W. Zhou, X. Gu, Z. Chen, and Z. Zhou, Direct chiral resolution and its application to the determination of fungicide benalaxyl in soil and water by high performance liquid chromatography, Anal. Chim. Acta 555 (2006), pp. 210-216.
55. J. W. Kim, H. S. Jang, J. G. Kim, H. Ishibashi, M. Hirano, K. Nasu, N. Ichikawa, Y. Takao, R. Shinohara, and K. Arizono, Occurrence of pharmaceutical and personal care products (PPCPs) in surface water from Mankyung River, South Korea, J. Health Sci. 55 (2009), pp. 249-258.
56. C. V. Antoniou, E. E. Koukouraki, and E. Diamadopoulos, Analysis of selected pharmaceutical compounds and endocrine disruptors in municipal wastewater using solid-phase microextraction and gas chromatography, Water Environ. Res. 81 (2009), pp. 664-669.
57. A. Y.-C. Lin, T.-H. Yu, and S. K. Lateef, Removal of pharmaceuticals in secondary wastewater treatment processes in Taiwan, J. Hazard. Mater. 167 (2009), pp. 1163-1169.
58. T. Okuda, N. Yamashita, H. Tanaka, H. Matsukawa, and K. Tanabe, Development of extraction method of pharmaceuticals and their occurrences found in Japanese wastewater treatment plants, Environ. Int. 35 (2009), pp. 815-820.
59. J. L. Santos, I. Aparicio, M. Callejón, and E. Alonso, Occurrence of pharmaceutically active compounds during 1-year period in wastewaters from four wastewater treatment plants in Seville (Spain), J. Hazard. Mater. 164 (2009), pp. 1509-1516.
60. J. L. Conkle, J. R. White, and C. D. Metcalfe, Reduction of pharmaceutically active compounds by a lagoon wetland wastewater treatment system in Southeast Louisiana, Chemosphere 73 (2008), pp. 1741-1748.
61. J. H. Al-Rifai, C. L. Gabelish, and A. I. Schäfer, Occurrence of pharmaceutically active and non-steroidal estrogenic compounds in three different wastewater recycling schemes in Australia, Chemosphere 69 (2007), pp. 803-815.
62. P. Westerhoff, Y. Yoon, S. Snyder, and E. Wert, Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes, Environ. Sci. Technol. 39 (2005), pp. 6649-6663.
63. W. Hua, E. R. Bennett, and R. J. Letcher, Ozone treatment and the depletion of detectable pharmaceuticals and atrazine herbicide in drinking water sourced from the upper Detroit River, Ontario, Canada, Water Res. 40 (2006), pp. 2259-2266.
64. K. M. Onesios, J. T. Yu, and E. J. Bouwer, Biodegradation and removal of pharmaceuticals and personal care products in treatment systems: A review, Biodegradation 20 (2009), pp. 441-466.
65. J. B. Quintana, S. Weiss, and T. Reemtsma, Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor, Water Res. 39 (2005), pp. 2654-2664.
66. B. Kasprzyk-Hordern, R. M. Dinsdale, and A. J. Guwy, The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK, Water Res. 42 (2008), pp. 3498-3518.
67. J. L. Zhou, Z. L. Zhang, E. Banks, D. Grover, and J. Q. Jiang, Pharmaceutical residues in wastewater treatment works effluents and their impact on receiving river water, J. Hazard. Mater. 166 (2009), pp. 655-661.
68. M. D. Hernando, M. J. Gomez, A. Aguera, and A. R. Fernandez-Alba, LC-MS analysis of basic pharmaceuticals (beta-blockers and anti-ulcer agents) in wastewater and surface water, Trends Anal. Chem. 26 (2007), pp. 581-594.
69. B. Kasprzyk-Hordern, R. M. Dinsdale, and A. J. Guwy, Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry, J. Chromatogr. A 1161 (2007), pp. 132-145.
70. J. D. Cahill, E. T. Furlong, M. R. Burkhardt, D. Kolpin, and L. G. Anderson, Determination of pharmaceutical compounds in surface-and ground-water samples by solid-phase extraction and high-performance liquid chromatography-electrospray ionization mass spectrometry, J. Chromatogr. A 1041 (2004), pp. 171-180.
71. K. Fent, A. A. Weston, and D. Camidana, Review: Ecotoxicology of human pharmaceuticals, Aquat. Toxicol. 76 (2006), pp. 122-159.
72. S. Pérez and D. Barceló, Applications of LC-MS to quantitation and evaluation of the environmental fate of chiral drugs and their metabolites, Trends Anal. Chem. 27 (2008), pp. 836-846.
73. C. Volland, H. Sun, and L. Z. Benet, Stereoselective analysis of fenoprofen and its metabolites, J. Chromatogr. B 534 (1990), pp. 127-138.
74. A. R. M. de Oliveira, F. J. M. de Santana, and P. S. Bonato, Stereoselective determination of the major ibuprofen metabolites in human urine by off-line coupling solid-phase microextraction and highperformance liquid chromatography, Anal. Chim. Acta 538 (2005), pp. 25-34.
75. S. Selke, M. Scheurell, M. R. Shah, and H. Hühnerfuss, Identification and enantioselective gas chromatographic mass-spectrometric separation of O-desmethylnaproxen, the main metabolite of the drug naproxen, as a new environmental contaminant, J. Chromatogr. A 1217 (2010), pp. 419-423.
76. C. S. Wong and S. L. MacLeod, JEM Spotlight: Recent advances in analysis of pharmaceuticals in the aquatic environment, J. Environ. Monitor. 11 (2009), pp. 923-936.
77. H. Huhnerfuss, J. Faller, R. Kallenborn, W. A. Konig, P. Ludwig, B. Pfaffenberger, M. Oehme, and G. Rimkus, Enantioselective and nonenantioselective degradation of organic pollutants in the marine ecosystem, Chirality 5 (1993), pp. 393-399.
78. S. Qin and J. Gan, Abiotic enantiomerization of permethrin and cypermethrin: Effects of organic solvents, J. Agric. Food Chem. 55 (2007), pp. 5734-5739.
79. Y. Ma, C. Xu, Y. Wen, and W. Liu, Enantioselective separation and degradation of the herbicide dichlorprop methyl in sediment, Chirality 21 (2009), pp. 480-483.
80. I. Harrison, G. M. Williams, and C. A. Carlick, Enantioselective biodegradation of mecoprop in aerobic and anaerobic microcosms, Chemosphere 53 (2003), pp. 539-549.
81. H. Tan, Y. Cao, T. Tang, K. Qian, W. L. Chen, and J. Li, Biodegradation and chiral stability of fipronil in aerobic and flooded paddy soils, Sci. Total Environ. 407 (2008), pp. 428-437.
82. Á. Sebok, A. Vasanits-Zsigrai, G. Palkó, G. Záray, and I. Molnár-Perl, Identification and quantification of ibuprofen, naproxen, ketoprofen and diclofenac present in waste-waters, as their trimethylsilyl derivatives, by gas chromatography mass spectrometry, Talanta 76 (2008), pp. 642-650.
83. M. Petrovic, M. J. L. D. Alda, S. Diaz-Cruze, C. Postigo, J. Radjenovic, M. Gros, and D. Barcelo, Fate and removal of pharmaceuticals and illicit drugs in conventional and membrane bioreactor wastewater treatment plants and by riverbank filtration, Phil. Trans. R. Soc. A 367 (2009), pp. 3979-4003.
84. S. Perez and D. Barcelo, Application of advanced MS techniques to analysis and identification of human and microbial metabolites of pharmaceuticals in the aquatic environment Trends Anal. Chem. 26 (2007), pp. 494-514.
85. M. W. Skidmore, Derivatization for chromatographic revolution of optically active compounds, in Handbook of Derivatives for Chromatography, K. Blau and J. N. Halket (Eds.), Wiley, Chichester, 1993, pp. 215-252.
86. N. M. Davies, Methods of analysis of chiral non-steroidal anti-inflammatory drugs, J. Chromatogr. B 691 (1997), pp. 229-261.
87. P. O. Carvalho, Q. B. Cass, S. A. Calafatti, F. J. Contesini, and R. Bizaco, Review - Alternatives for the separation of drug enantiomers: ibuprofen as a model compound, Braz. J. Chem. Eng. 23 (2006), pp. 291-300.
88. A. P. Kumar, D. Jin, and Y.-I. Lee, Recent development on spectroscopic methods for chiral analysis of enantiomeric compounds, App. Spectrosc. Rev. 44 (2009), pp. 267-316.
89. L. He and T. E. Beesley, Applications of enantiomeric gas chromatography: A review, J. Liq. Chromatogr. R. 28 (2005), pp. 1075-1114.
90. P. Mikus and K. Marakova, Advanced CE for chiral analysis of drugs, metabolites and biomarkers in biological samples, Electrophoresis 30 (2009), pp. 2773-2802.
91. T. Arai, Chiral separation of pharmaceuticals possessing a carboxy moiety, J. Chromatogr. B 717 (1998), pp. 295-311.
92. T. J. Ward, Chiral Separations, Anal. Chem. 72 (2000), pp. 4521-4528.
93. J. Bojarski, H. Y. Aboul-Enein, and A. Ghanem, What's new in chromatographic enantioseparations, Curr. Anal. Chem. 1 (2005), pp. 59-77.
94. T. J. Ward, Chiral Separations, Anal. Chem. 74 (2002), pp. 2863-2872.
95. T. J. Ward and D.-M. Hamburg, Chiral Separations, Anal. Chem. 76 (2004), pp. 4635-4644.
96. T. J. Ward, Chiral Separations, Anal. Chem. 78. (2006), pp. 3947-3956.
97. T. J. Ward and B. A. Baker, Chiral Separations, Anal. Chem. 80 (2008), pp. 4363-4372.
98. G. Gubitz and M. G. Schmid, Chiral separation by chromatographic and electromigration techniques. A review, Biopharm. Drug. Dispos. 22 (2001), pp. 291-336.
99. W. Lindler, Recent development in HPLC enantioseparation - A selected review, Chromatographia 24 (1987), pp. 97-107.
100. S. Andersson and S. G. Allenmark, Preparative chiral chromatographic resolution of enantiomers in drug discovery, J. Biochem. Bioph. Meth. 54 (2002), pp. 11-23. (Pubitemid 36126133)
101. J. Haginaka, Protein-based chiral stationary phases for high-performance liquid chromatography enantioseparations, J. Chromatogr. A 906 (2001), pp. 253-273.
102. Y. Okamoto and T. Ikai, Chiral HPLC for efficient resolution of enantiomers, Chem. Soc. Rev. 37 (2008), pp. 2593-2608.
103. G. Gubitz, Chiral separation principles in chromatographic and electromigration techniques, Mol. Biotechnol. 32 (2006), pp. 159-179.
104. R. Bhushan and D. Gupta, HPLC resolution of thioridazine enantiomers from pharmaceutical dosage form using cyclodextrin-based chiral stationary phase, J. Chromatogr. B 837 (2006), pp. 133-137.
105. H. J. Choi and M. H. Hyun, Liquid chromatographic chiral separations by crown ether-based chiral stationary phases, J. Liq. Chromatogr. R. T 30 (2007), pp. 853-875.
106. I. Ali, K. Saleem, I. Hussain, V. D. Gaitonde, and H. Y. Aboul-Enein, Polysaccharides chiral stationary phases in liquid chromatography, Sep. Purif. Rev. 38 (2009), pp. 97-147.
107. T. E. Beesley and J.-T. Lee, Method development strategy and applications update for CHIROBIOTIC chiral stationary phases, J. Liq. Chromatogr. R. T 32 (2009), pp. 1733-1767.
108. J. Haginaka, Recent progresses in protein-based chiral stationary phases for enantioseparations in liquid chromatography, J. Chromatogr. B 875 (2008), pp. 12-19.
109. T. Toyo'oka, Resolution of chiral drugs by liquid chromatography based upon diastereomer formation with chiral derivatization reagents, J. Biochem. Bioph. Meth. 54 (2002), pp. 25-56.
110. I. Ilisz, R. Berkecz, and A. Péter, Application of chiral derivatizing agents in the high-performance liquid chromatographic separation of amino acid enantiomers: A review, J. Pharmaceut. Biomed. 47 (2008), pp. 1-15.
111. E. B. Christensen, S. H. Hansen, and S. N. Rasmussen, Assay of tocainide enantiomers in plasma by solidphase extraction and indirect chiral high-performance liquid chromatography after derivatization with (-) - menthyl chloroformate, J. Chrom. B: Biomed. Sci. Appl. 670 (1995), pp. 243-249.
112. Y.-X. Jin, Y.-H. Tang, and S. Zeng, Analysis of flubiprofen, ketoprofen and etodolac enantiomers by precolumn derivatization RP-HPLC and application to drug-protein binding in human plasma, J. Pharmaceut. Biomed. Anal. 46 (2008), pp. 953-958.
113. R. T. Foster and F. Jamali, High-performance liquid chromatographic assay of ketoprofen enantiomers in human plasma and urine, J. Chrom. Biomed. Appl. 416 (1987), pp. 388-393.
114. H. Spahn, Formation of diastereomeric derivatives of 2-arylpropionic acids using-leucinamide, J. Chrom. Biomed. Appl. 423 (1987), pp. 334-339.
115. S. Bjorkman, Determination of the enantiomers of indoprofen in blood plasma by high-performance liquid chromatography after rapid derivatization by means of ethyl chloroformate, J. Chromatogr. B 339 (1985), pp. 339-346.
116. M. Vakily and F. Jamali, Pharmacokinetics or tiaprofenic acids in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods, J. Pharm. Sci. 85 (1996), pp. 638-642.
117. J. Goto, N. Goto, and T. Nambara, Separation and determination of naproxen enantiomers in serum by high-performance liquid chromatography, J. Chromatogr. B 239 (1982), pp. 559-564. (Pubitemid 12066243)
118. R. A. Carr, R. T. Foster, and N. H. Bhanji, Sterospecific high-performance liquid chromatographic assay of sotalol in plasma, Pharmaceut. Res. 8 (1991), pp. 1195-1198.
119. S. Millán, M. A. Goicolea, A. Sánchez, A. Gómez-Caballero, M. C. Sampedro, N. Unceta, and R. J. Barrio, Stereoselective determination of demethyl-and didemethyl-citalopram in rat plasma and brain tissue by liquid chromatography with fluorescence detection using precolumn derivatization, Biomed. Chromatogr. 22 (2008), pp. 265-271.
120. D. Jin, A. P. Kumar, G.-C. Song and Y.-I. Lee, Determination of thyroxine enantiomers in pharmaceutical formulation by high-performance liquid chromatography-mass spectrometry with precolumn derivatization, Microchem. J. 88 (2008), pp. 62-66.
121. V. Schurig, Separation of enantiomers by gas chromatography, J. Chromatogr. A 906 (2001), pp. 275-299.
122. M. Petrovic, Z. Debeljak and N. Blazevic, Optimization of gas chromatographic method for the enantioseparation of arylpropionic non-steroidal antiinflammatory drug methyl esters, J. Pharmaceut. Biomed. 39 (2005), pp. 531-534.
123. L. Chytil, M. Stícha, O. Matousková, F. Perlík, and O. Slanar, Enatiomeric determination of tramadol and odesmethyltramadol in human urine by gas chromatography-mass spectrometry, J. Chromatogr. B 877 (2009), pp. 1937-1942.
124. N. R. Srinivas, W. C. Shyu, and H. H. Barbhaiya, Gas chromatographic determination of enantiomers as diastereomers following pre-column derivatization and applications to pharmacokinetic studies: A review, Biomed. Chromatogr. 9 (1995), pp. 1-9.
125. K.-R. Kim, J. Lee, D. Ha, and J. H. Kim, Configurational analysis of chiral acids as O-trifluoroacetylated (-)-menthyl esters by achiral dual-capillary column gas chromatography, J. Chromatogr. A 891 (2000), pp. 257-266.
126. F. Pehourcq, F. Lagrange, L. Labat, and B. Bannwarth, Simultaneous measurement of flurbiprofen, ibuprofen, and ketoprofen enantiomer concentrations in plasma using L-leucinamide as the chiral coupling component, J. Liq. Chromatogr. 18 (1995), pp. 3969-3979.
127. M. R. Wright and F. Jamali, Limited extent of stereochemical conversion of chiral non-steroidal antiinflammatory drugs induced by derivatization methods employing ethyl chloroformate, J. Chromatogr-Biomed. 616 (1993), pp. 59-65.
128. Y. Fujimoto, K. Ishi, H. Nishi, N. Tsumagari, T. Kakimoto, and R. Shimizu, New derivatization reagents for the resolution of carboxylic acid enantiomers by high-performance liquid chromatography, J. Chromatogr. A 402 (1987), pp. 344-348.
129. M.-J. Paik, Y. Lee, J. Goto, and K.-R. Kim, Chiral discrimination of multiple profens as diastereomeric (R) - (+)-1-phenylethylamides by achiral dual-column gas chromatography, J. Chromatogr. B 803 (2004), pp. 257-265.
130. M.-J. Paik, D.-T. Nguyen, and K.-R. Kim, Enantioseparation of flurbiprofen and ketoprofen in patches and in urine by achiral gas chromatography, Arch. Pharm. Res. 27 (2004), pp. 1295-1301.
131. M.-J. Paik and K.-R. Kim, Optical purity determination of (S)-ibuprofen in tablets by achiral gas chromatography, Arch. Pharm. Res. 27 (2004), pp. 820-824.
132. A. Carlson and O. Gyllenhaal, Separation of carboxylic acid enantiomers by gas chromatography after rapid derivatization with (R) - or (S)-1-phenylethylamine after activation by ethyl chloroformate, J. Chromatogr. A 508 (1990), pp. 333-339.
133. B. Blessington, N. Crabb, S. Karkee, and A. Northage, Chromatographic approaches to the quality control of chiral proprionate anti-inflammatory drugs and herbicides, J. Chromatogr. A 469 (1989), pp. 183-190.
134. N. N. Singh, F. M. Pasutto, R. T. Coutts, and F. Jamali, Gas chromatographic separation of optically active anti-inflammatory 2-arylpropionic acids using (+) - or (-)-amphetamine as derivatizing reagent, J. Chromatogr. B 378 (1986), pp. 125-135.
135. P. S. Bonato, Recent advances in the determination of enantiomeric drugs and their metabolites in biological fluids by capillary electrophoresis-mediated microanalysis, Electrophoresis 24 (2003), pp. 4078-4094.
136. B. Preinerstorfer, M. Lammerhofer, and W. Lindner, Advances in enantioselective separations using electromigration capillary techniques, Electrophoresis 30 (2009), pp. 100-132.
137. S. A. Zaidi and W. J. Cheong, Long open tubular molecule imprinted polymer capillary columns with excellent separation efficiencies in chiral and nonchiral separation by capillary electrochromatography, Electrophoresis 30 (2009), pp. 1603-1607.
138. Y. Huo and W. T. Kok, Recent applications in CEC, Electrophoresis 29 (2008), pp. 80-93.
139. B.-L. Chu, B. Guo, H. Zuo, Z. Wang, and J.-M. Lin, Simultaneous enantioseparation of antiparkinsonian medication rotigotine and related chiral impurities by capillary zone electrophoresis using dual cyclodextrin system, J. Pharmaceut. Biomed. 46 (2008), pp. 854-859.
140. P. Mikus, K. Maráková, J. Marák, I. Nemec, I. Valásková, and E. Havránek, Direct quantitative determination of amlodipine enantiomers in urine samples for pharmacokinetic study using on-line coupled isotachophoresis-capillary zone electrophoresis separation method with diode array detection, J. Chromatogr. B 875 (2008), pp. 266-272.
141. L. T. Taylor, Supercritical fluid chromatography, Anal. Chem. 80 (2008), pp. 4285-4294.
142. C. B'Hymer, M. Montes-Bayon, and J. A. Caruso, Marfey's reagent: Past, present, and future uses of 1-fluoro-2, 4-dinitrophenyl-5-L-alanine amide, J. Sep. Sci 26 (2003), pp. 7-19.
143. S. Rubio and D. Pérez-Bendito, Recent advances in environmental analysis, Anal. Chem. 81 (2009), pp. 4601-4622.
144. C. Coetsier, L. Lin, B. Roig, and E. Touraud, Integrated approach to the problem of pharmaceutical products in the environment: an overview, Anal. Bioanal. Chem. 387 (2007), pp. 1163-1166.
145. C. Chen, Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine, Curr. Med. Chem. 15 (2008), pp. 2173-2191.
146. J. S. Markowitz and K. S. Patrick, Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J. Clin. Pyschopharm. S54 28 (2008), pp. S54-S61.